Royalty Pharma RPRX Trelegy — Milestone payable
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:MilestonePaymentAccruedButNotPaid.
The official record: Royalty Pharma’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's trelegy — milestone payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's trelegy — milestone payable?
- Royalty Pharma (RPRX) reported trelegy — milestone payable of $12.5M in Q4 2025.
- How has Royalty Pharma's trelegy — milestone payable changed year-over-year?
- Royalty Pharma's trelegy — milestone payable decreased by 0.0% year-over-year, from $12.5M to $12.5M.
- What does trelegy — milestone payable mean?
- This metric represents the contractual obligation to make one-time payments triggered by the achievement of specific regulatory, clinical, or commercial milestones related to a licensed pharmaceutical asset. These payments are distinct from recurring royalty streams and reflect the realization of value-inflection events within the product's lifecycle. Monitoring these obligations is essential for assessing near-term cash outflow requirements and the progress of development-stage assets.